Condition
Respiratory Virus Infection
Total Trials
6
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 4 (1)
Trial Status
Completed3
Withdrawn1
Active Not Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07287137Phase 4Active Not Recruiting
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
NCT05084898Not ApplicableCompleted
Preventing Respiratory Viral Illness Invisibly
NCT02601365Phase 1Withdrawn
Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia
NCT03816059UnknownPrimary
Respiratory Virus Infections in Acutely Hospitalized Adult Patients With Pulmonary and Extrapulmonary Complications
NCT02538770Not ApplicableCompletedPrimary
Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization
NCT01167361CompletedPrimary
Epidemiology Of Respiratory Virus Infections In Children
Showing all 6 trials